Mouse Anti-Human VEGFR-2/KDR
Slide this table
Cat-Nr. | 101-M35 |
Size | 100 µg |
Price | 380 € |
Category | Monoclonal Antibody |
Clone Nr. | (#2F66) |
Isotype | IgG1 |
Species Reactivity | Human |
Formulation | lyophilized |
Buffer | PBS |
Reconstitution | Centrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml. |
Stability and Storage | Lyophilized samples are stable for 2 years from date of receipt when stored at -20°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least six months without detectable loss of activity. |
Preparation | This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with human VEGFR-2 N-terminal recombinant protein. IgG1 fraction of the tissue culture supernatant was purified by Protein G affinity chromatography. |
Antigen | human VEGFR-2 N-terminal fragment |
Application | WB, IHC, ELISA |
Synonyms | vascular endothelial growth factor receptor-2 ; KDR; FLK1; CD309; VEGF receptor 2; VEGFR2; kinase insert domain protein receptor |
Description | VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis. |
Uniprot ID | P35968 |
Protein RefSeq | NP_002244.1 |
mRNA RefSeq | NM_002253.2 |
All prices plus VAT + possible delivery charges